Seeking Alpha·Sep 10, 2026
Syndax Pharmaceuticals, Inc. (SNDX) Presents at Citigroup's Biopharma Back to School Summit 2026 TranscriptSyndax Pharmaceuticals, Inc. (SNDX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Syndax Pharmaceuticals is transitioning from a clinical-stage to a pre-commercial entity, evidenced by a 627.8% year-over-year revenue surge to $172.4M in the trailing twelve months, driven largely by a $72.8M milestone payment from the Incyte collaboration. H...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 4, 2026 | -$0.55-22.9% vs -$0.45 | $73M-8.3% vs $79M |
Q2 2026 Apr 30, 2026 | -$0.48+18.6% vs -$0.59 | $65M-7.0% vs $70M |
Q1 2026 Feb 26, 2026 | -$0.78-33.6% vs -$0.58 | $69M+6.9% vs $64M |
Q4 2025 Nov 3, 2025 | -$0.70+5.4% vs -$0.74 | $46M-27.6% vs $63M |
Syndax Pharmaceuticals, Inc. (SNDX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on September 1, 2026, the Company granted inducement awards to purchase up to 175,000 shares of common stock to nineteen new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A.
BlackRock Inc. bought a new position in Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) in the undefined quarter, according to its most recent disclosure with the SEC. The firm bought 9,020,006 shares of the company's stock, valued at approximately $197,177,000. BlackRock Inc. owned 10.18% of Syndax Pharmaceuticals at the end of the most recent quarter.
Benchmark SNDX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Syndax Pharmaceuticals, Inc. (SNDX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $17.64 | $1.56B | -5.36 | 627.84% | -165.6% | -161.82% | — | |
| $115.47 | $9.5B | -31.29 | -16.72% | -285.41% | -21.5% | — | |
| $34.54 | $7.13B | -12.47 | — | -7585.86% | -69.59% | — | |
| $190.74 | $40.55B | -32.06 | — | — | -96.44% | — | |
| $56.00 | $8.57B | 20.22 | 87.32% | 55.22% | 72.3% | — | |
| $282.12 | $7.87B | -20.93 | -100% | — | -34.15% | — |
Syndax Pharmaceuticals, Inc. (SNDX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Syndax Pharmaceuticals, Inc. (SNDX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 4, 2026·SEC
Jul 14, 2026·SEC
Jun 10, 2026·SEC
Get notified when SNDX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Syndax Pharmaceuticals, Inc. (SNDX) stock FAQ — growth, dividends, profitability & financials explained
Syndax Pharmaceuticals, Inc. (SNDX) reported $252.0M in revenue for fiscal year 2025.
Syndax Pharmaceuticals, Inc. (SNDX) grew revenue by 627.8% over the past year. This is strong growth.
Syndax Pharmaceuticals, Inc. (SNDX) reported a net loss of $220.8M for fiscal year 2025.
Syndax Pharmaceuticals, Inc. (SNDX) has a return on equity (ROE) of -161.8%. Negative ROE indicates the company is unprofitable.
Syndax Pharmaceuticals, Inc. (SNDX) had negative free cash flow of $220.9M in fiscal year 2025, likely due to heavy capital investments.
